Shares in Danone, the renowned French consumer goods manufacturer, escalated approximately 7% following the release of second-quarter sales which outperformed predictions. This surge of success is largely attributed to a soaring demand for infant milk formula and medical nutrition products in China.
The impressive surge in demand offset challenges faced in other markets. There were sluggish sales in the water division in Latin America due to unfavourable weather conditions in Mexico, while a highly competitive market in the US resulted in slow coffee creamer sales. Nevertheless, Danone, known for household brands such as Evian water and Activia yoghurt, reported a 4.1% increase in second-quarter sales on a like-for-like basis, outstripping anticipated growth of 3.8%.
The financials revealed Danone’s recurring operating income for the first half of 2025 to be 1.811 billion euros (US$2.09 billion). This represents a margin of 13.2% of sales, an increase from 12.7% from the previous year. The company also reassured investors by restating its 2025 full-year forecast, in line with its mid-term goal of achieving like-for-like sales growth between 3% and 5%, and a faster growth rate for recurring operating income.
Speaking about the company’s performance, CEO Antoine de Saint-Affrique commented, “The first-half performance reflected the strength and resilience of our health-focused portfolio.” The company’s aim, according to de Saint-Affrique, is to consistently perform while transforming and enhancing areas requiring attention. This includes the plant-based business and coffee creamers in the US.
Sales in China, North Asia and Oceania also had an exceptional quarter, increasing 12.4% on a like-for-like basis. Specialized Nutrition also experienced double-digit growth, fuelled by strong demand in both the Infant Milk Formula and Medical Nutrition segments.
North America also saw a 2.3% rise in sales for the quarter, bolstered by a surge in protein product sales such as Oikos brand Greek yoghurt. The coffee creamers sector also showed signs of recovery following supply chain issues in the first quarter.
Danone has also been leveraging its cash reserves for strategic acquisitions to amplify its focus on health and science, and build resilience against market volatility. The company recently acquired the Akkermansia Company, a Belgian biotics firm and also holds a majority stake in Kate Farms, a US-based organic formula and shake manufacturer.
What contributed to Danone’s surge in shares?
The surge in shares was primarily due to the impressive second-quarter sales that exceeded expectations, driven by a high demand for infant milk formula and medical nutrition products in China.
How is Danone planning to boost its focus on health and science?
Danone has been utilizing its cash for strategic acquisitions that align with the company’s focus on health and science. It has recently acquired a Belgian biotics firm, Akkermansia Company, and also holds a majority stake in Kate Farms, a US-based organic formula and shake manufacturer.
What was the significance of the first half performance for Danone?
The first-half performance demonstrated the resilience and strength of Danone’s health-centric portfolio and its ability to perform consistently while transforming and enhancing areas that require attention. This is evidenced by a 4.1% increase in second-quarter sales on a like-for-like basis, which surpassed the anticipated growth of 3.8%.
